The 2018 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2018) was held in Glasgow, UK, from 28 to 31 October 2018.

Conference highlights

PrEP science

How safe is PrEP? Meta-analysis finds no increased risk of serious side effects

Conference bulletins

Read our HIV Glasgow conference bulletin.

Treatment-experienced people

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant patients shows.

Generic medicines

Generic PrEP bought online has correct amounts of emtricitabine and tenofovir.

New and experimental HIV treatments

Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left.

Child developmental issues

Neural tube defects and integrase inhibitors: studies show no further evidence of increased risk.

Starting treatment

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir.

People who inject drugs

How has Glasgow responded to an outbreak of HIV among people who inject drugs?

Starting treatment

Bictegravir matches dolutegravir in first-line treatment.

aidsmap news from HIV Glasgow 2018

← First1Next →

Editors' picks from other sources

News bulletins

Sign up for our email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Official conference website

Find out more on the official conference website.

Visit the conference website >

Conference bulletin

Visit our HIV Glasgow 2018 conference bulletins page.

HIV Glasgow 2018 conference bulletins >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.